ERβ was found to inactivate FOXO1 [105] and reduce the expression of GULP1 [118] via binding to their promoters in bladder cancer cells and thereby induce sensitivity to cisplatin. This evidence concerns the gene ESR2 and urinary bladder carcinoma.